Pegylated Interferons for the Treatment of Chronic Hepatitis C
- 1 January 2010
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 70 (2) , 147-165
- https://doi.org/10.2165/11531990-000000000-00000
Abstract
Chronic infection with hepatitis C virus (HCV) is a major healthcare problem, affecting an estimated 170 million people worldwide. Interferon-α has formed the basis of treatment regimens since the...Keywords
This publication has 95 references indexed in Scilit:
- Impact of High-Dose Peginterferon Alfa-2A on Virological Response Rates in Patients with Hepatitis C Genotype 1: a Randomized Controlled Trial† ‡Hepatology, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Expert opinion on the treatment of patients with chronic hepatitis CJournal of Viral Hepatitis, 2009
- Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients†Hepatology, 2009
- Safety of peginterferon in the treatment of chronic hepatitis CExpert Opinion on Drug Safety, 2008
- Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristicsHepatology, 2008
- A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut, 2007
- Peginterferon-??-2a (40kD) Plus RibavirinDrugs, 2004
- Peginterferon ??-2a (40kD) [Pegasys??] Improves HR-QOL Outcomes Compared with Unmodified Interferon ??-2a [Roferon??-A]PharmacoEconomics, 2003